Sex: U
Vaccine: DTAP, DTAP, DTAP, DTAP
Symptoms: Inappropriate schedule of product administration, Incomplete course of vaccination, Interchange of vaccine products, Product administered to patient of inappropriate age
Clinical narrative: Inocmplete course of vaccination; DAPTACEL was received on 12/29/16 , INFANRIX on 12/30/19 and 8/24/21.; Inappropriate age at vaccine administration; dtap series DAPTACEL then INFANRIX; Inappropriate age at vaccine administration; This case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a 7-year-old patient who received DTPa (Infanrix) for prophylaxis.   Co-suspect products included dtpa vaccine pre-filled syringe device (Infanrix Pre-Filled Syringe Device) injection syringe for prophylaxis, DTPa (Infanrix) for prophylaxis, dtpa vaccine pre-filled syringe device (Infanrix Pre-Filled Syringe Device) injection syringe for prophylaxis, DTPa (Infanrix) for prophylaxis, dtpa vaccine pre-filled syringe device (Infanrix Pre-Filled Syringe Device) injection syringe for prophylaxis and DIPHTHERIA VACCINE TOXOID + PERTUSSIS TOXOID + TETANUS VACCINE TOXOID (DAPTACEL) for prophylaxis.   On 24th August 2021, the patient received the 2nd dose of Infanrix and Infanrix Pre-Filled Syringe Device. On 30th December 2019, the patient received the 1st dose of Infanrix and Infanrix Pre-Filled Syringe Device. On an unknown date, the patient received the 3rd dose of Infanrix and Infanrix Pre-Filled Syringe Device. On 29th December 2016, the patient received DAPTACEL. On 30th December 2019, not applicable after receiving Infanrix, Infanrix Pre-Filled Syringe Device, Infanrix and Infanrix Pre-Filled Syringe Device and unknown after receiving Infanrix and Infanrix Pre-Filled Syringe Device, the patient experienced interchange of vaccine products and inappropriate age at vaccine administration. On 24th August 2021, the patient experienced drug dose administration interval too long and inappropriate age at vaccine administration. On an unknown date, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the drug dose administration interval too long, inappropriate age at vaccine administration, interchange of vaccine products, inappropriate age at vaccine administration and incomplete course of vaccination were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The age at vaccination was unknown. The patient received DAPTACEL (other manufacturer ) and then received INFANRIX, which led to interchange of vaccine products and inappropriate age at vaccine administration. The patient received INFANRIX 2nd dose late which led to inappropriate age at vaccine administration and lengthening of vaccination schedule. The reporter asked if the 7 year old patient could compete the dtap series with boostrix. Till the time of reporting the patient did not complete vaccination series which led to incomplete course of vaccination. The reporter consented to follow up. No other information was available.